Sglt2 inhibitors examples
Pro Research Analysisby 
Searched over 200M research papers
Examples of SGLT2 Inhibitors
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of medications primarily used to manage type 2 diabetes by promoting the excretion of glucose through urine. These drugs have also shown benefits in cardiovascular and renal outcomes. Below are some key examples of SGLT2 inhibitors and their associated benefits and risks.
Empagliflozin (EMPA)
Cardiovascular and Renal Benefits: Empagliflozin has been shown to reduce cardiac cytosolic sodium and calcium concentrations, which can be beneficial for heart health. It also induces coronary vasodilation, which improves blood flow in the heart . Additionally, empagliflozin significantly reduces the risk of major adverse cardiovascular events, hospitalization for heart failure, and progression of renal disease Zelniker2019Neuen2019.
Mechanisms of Action: Empagliflozin works by inhibiting the Na+/H+ exchanger, which helps in lowering cytosolic sodium levels in cardiomyocytes . This mechanism is thought to contribute to its cardiovascular benefits.
Dapagliflozin (DAPA)
Cardiovascular and Renal Benefits: Dapagliflozin has been found to reduce the risk of heart failure and major adverse cardiovascular events. It also shows a significant reduction in the progression of renal disease Zelniker2019Neuen2019.
Mechanisms of Action: Similar to empagliflozin, dapagliflozin inhibits the Na+/H+ exchanger, reducing cytosolic sodium levels in heart cells. However, it does not induce coronary vasodilation as empagliflozin does .
Canagliflozin (CANA)
Cardiovascular and Renal Benefits: Canagliflozin has demonstrated a reduction in the risk of cardiovascular events and heart failure. It also significantly lowers the risk of kidney failure, including the need for dialysis or transplantation Zelniker2019Neuen2019.
Mechanisms of Action: Canagliflozin inhibits the Na+/H+ exchanger, reducing cytosolic sodium levels in cardiomyocytes and inducing coronary vasodilation . This contributes to its cardiovascular and renal benefits.
Risks and Side Effects
Diabetic Ketoacidosis: One of the significant risks associated with SGLT2 inhibitors is an increased likelihood of diabetic ketoacidosis. This condition can occur due to multiple mechanisms, including reduced insulin doses and increased glucagon secretion Taylor2015Alkabbani2021.
Other Adverse Events: While SGLT2 inhibitors are generally well-tolerated, they can cause side effects such as urinary tract infections and genital infections due to increased glucose in the urine .
Conclusion
SGLT2 inhibitors like empagliflozin, dapagliflozin, and canagliflozin offer substantial benefits in managing type 2 diabetes and reducing cardiovascular and renal risks. However, they also come with potential side effects, including an increased risk of diabetic ketoacidosis. Understanding these benefits and risks can help in optimizing treatment plans for patients with type 2 diabetes.
Sources and full results
Most relevant research papers on this topic